Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages

Atyr PHARMA INC (NASDAQ:ATYR) has received an average recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $18.60.

Several equities analysts have issued reports on ATYR shares. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Friday, March 14th. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They set an “overweight” rating on the stock.

Institutional Investors Weigh In On Atyr PHARMA

A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. Federated Hermes Inc. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $53,093,000. Point72 Asset Management L.P. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $17,677,000. Tikvah Management LLC acquired a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $8,908,000. Woodline Partners LP acquired a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $4,628,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Stock Performance

NASDAQ:ATYR opened at $3.84 on Friday. The firm has a market capitalization of $322.34 million, a PE ratio of -4.09 and a beta of 0.98. The business’s fifty day moving average price is $3.66 and its 200 day moving average price is $3.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.